<DOC>
	<DOCNO>NCT00004057</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine paclitaxel L-778,123 treating patient recurrent refractory solid tumor lymphomas .</brief_summary>
	<brief_title>Paclitaxel Plus L-778,123 Treating Patients With Recurrent Refractory Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose L-778,123 combine paclitaxel patient recurrent refractory solid tumor lymphomas . II . Evaluate safety , tolerability , dose limit toxicity regimen patient . III . Assess steady state plasma concentration various dos L-778,123 combine paclitaxel patient . IV . Evaluate radiologic tumor marker response regimen patient . V. Evaluate relationship ras mutation response regimen patient . OUTLINE : This dose escalation , multicenter study L-778,123 . Patients receive paclitaxel IV 3 hour follow within 24 hour L-778,123 IV 7 day . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response receive 2 course documentation response . Cohorts 1-3 patient receive escalate dos L-778,123 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A maximum 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor lymphoma recurrent refractory standard first line therapy Measurable evaluable disease No active inactive primary CNS malignancy No untreated active metastatic CNS malignancy No leukemia plasma cell dyscrasia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time normal ALT AST great 2.5 time normal Alkaline phosphatase great 4 time normal ( great 2 time normal increase great 25 % past 2 week ) PT , INR , aPTT great 1.2 time normal Renal : Creatinine great 1.5 time normal Electrolytes within 10 % normal range Cardiovascular : No prior grade 3 4 cardiac arrhythmia except atrial fibrillation No QTc interval 440 millisecond great electrocardiogram No QTc abnormalities No myocardial infarction , unstable angina , congestive heart failure within past 12 month Psychiatric : No mental legal incapacitation No concurrent significant emotional problem No prior psychiatric disorder Neurologic : No grade 2 high peripheral neuropathy No prior seizure disorder Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier contraception practice abstinence least 14 day , , least 14 day therapy No allergy latex , Cremophor ( find formulation cyclosporine vitamin K ) , paclitaxel HIV negative No HIV relate malignancy No active infection No prior significant retinal disorder disease At least 5 year since prior drug alcohol abuse PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No concurrent immunotherapy No concurrent colony stimulate factor epoetin alfa Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) At least 4 week since prior paclitaxel recover No prior high dose chemotherapy stem cell rescue No concurrent chemotherapy Endocrine therapy : At least 4 week since prior endocrine therapy ( except chronic LHRH agonist replacement therapy administer least 3 month ) No concurrent endocrine therapy except prophylactic steroid first course chemotherapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior surgery No concurrent surgery Permanent indwell central venous catheter require Other : At least 4 week since prior investigational agent ( include FDA approve drug nonFDA approve indication ) No concurrent medication prolong QTc interval ( e.g. , terfenadine , astemizole , cisapride , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , tricyclic antidepressant , haloperidol , risperidone , indapamide , dolasetron mesylate ) No concurrent potent inducer CYP3A ( e.g. , rifampin , phenobarbital , phenytoin , carbamazepine , troglitazone , rifabutin ) No concurrent benzodiazepine metabolize CYP3A ( e.g. , triazolam , alprazolam , midazolam ) No concurrent HMGCoA reductase inhibitor metabolize CYP3A No prophylactic medication first course chemotherapy except antihistamine H2 antagonist ( paclitaxel ) No 6 cup coffee equivalent caffeinated beverage per day At least 24 hour since prior alcohol consumption No alcohol consumption confine clinical research unit No 24 ounce beer , 8 ounce wine , 3 ounce whiskey equivalent hard liquor per day confine clinical research unit No concurrent illicit drug No concurrent prochlorperazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>